pCR

es-BC - HR positive - (neo)adjuvant (NA) breast cancer - HR positive es-BC - HR positive - (neo)adjuvant (NA)

versus trastuzumab plus endocrine therapy
trastuzumab emtansine vs. trastuzumab plus endocrine therapy 1 3.90 [2.10; 7.27], 1 RCT, I2=0%
unassessable degree of certainty